Redmile Group LLC Sells 292,824 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Redmile Group LLC lessened its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 21.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,100,432 shares of the company’s stock after selling 292,824 shares during the quarter. Kymera Therapeutics comprises approximately 3.1% of Redmile Group LLC’s portfolio, making the stock its 10th biggest position. Redmile Group LLC owned about 1.70% of Kymera Therapeutics worth $44,270,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. Blue Trust Inc. lifted its stake in shares of Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an additional 270 shares during the period. KBC Group NV lifted its position in Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after purchasing an additional 752 shares during the period. Tower Research Capital LLC TRC lifted its position in Kymera Therapeutics by 95.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company’s stock valued at $194,000 after purchasing an additional 2,350 shares during the period. Summit Investment Advisors Inc. boosted its holdings in Kymera Therapeutics by 9.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock valued at $198,000 after purchasing an additional 406 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in Kymera Therapeutics during the 4th quarter worth approximately $251,000.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $29.75 on Thursday. The business’s fifty day moving average price is $29.48 and its two-hundred day moving average price is $37.31. The stock has a market cap of $1.94 billion, a PE ratio of -12.71 and a beta of 2.18. Kymera Therapeutics, Inc. has a one year low of $19.45 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.82) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The business’s revenue for the quarter was up 114.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.69) earnings per share. As a group, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KYMR has been the topic of a number of analyst reports. Guggenheim restated a “buy” rating and issued a $52.00 price target on shares of Kymera Therapeutics in a research note on Monday. UBS Group decreased their target price on shares of Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday. Citigroup assumed coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $52.00 price target on the stock. Stephens reiterated an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, Bank of America lowered their target price on shares of Kymera Therapeutics from $47.00 to $44.00 and set a “neutral” rating on the stock in a research report on Monday. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $55.27.

Insider Activity

In other news, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares of the company’s stock, valued at $6,147,428.70. The trade was a 3.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares of the company’s stock, valued at $2,438,588.25. The trade was a 2.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,659 shares of company stock valued at $324,567 over the last 90 days. Insiders own 16.01% of the company’s stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.